DexCom, Inc. (NASDAQ:DXCM – Get Rating) CEO Kevin R. Sayer sold 45,607 shares of the stock in a transaction on Friday, January 20th. The shares were sold at an average price of $105.75, for a total value of $4,822,940.25. Following the sale, the chief executive officer now owns 426,645 shares of the company’s stock, valued at approximately $45,117,708.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
DexCom Stock Performance
NASDAQ DXCM opened at $106.03 on Wednesday. The stock has a 50-day simple moving average of $112.85 and a two-hundred day simple moving average of $99.36. The firm has a market capitalization of $40.95 billion, a P/E ratio of 195.45, a PEG ratio of 2.95 and a beta of 1.14. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $134.76. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.43 and a current ratio of 3.77.
DexCom (NASDAQ:DXCM – Get Rating) last released its quarterly earnings data on Thursday, October 27th. The medical device company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $769.60 million during the quarter, compared to analyst estimates of $752.67 million. DexCom had a return on equity of 13.27% and a net margin of 8.24%. On average, equities analysts forecast that DexCom, Inc. will post 0.79 earnings per share for the current year.
Institutional Investors Weigh In On DexCom
Analysts Set New Price Targets
Several analysts have recently commented on DXCM shares. Morgan Stanley increased their price objective on DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Jefferies Financial Group assumed coverage on DexCom in a report on Wednesday, October 12th. They set a “buy” rating and a $125.00 price objective for the company. Cowen raised their target price on DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. BTIG Research raised their target price on DexCom to $126.00 in a research note on Tuesday, November 1st. Finally, Raymond James raised their target price on DexCom from $101.00 to $125.00 and gave the stock an “outperform” rating in a research note on Friday, October 28th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $122.00.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.